{"status": "Ok", "redirect_url": "https://www.investor.jnj.com/investor-news/news-details/2026/Johnson--Johnson-study-shows-TREMFYA-guselkumab-is-the-first-and-only-IL-23-inhibitor-to-demonstrate-efficacy-in-perianal-fistulizing-Crohns-disease/default.aspx", "message": "News view counter 703069 successfully enlarged"}